What Fluor-Vigantoletten Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed to help manage symptoms associated with systemic imbalance and physiological activity. The active substances are relevant in contexts involving heightened systemic burden. The high-level therapeutic domains address symptoms related to inflammatory or irritative states and potential strain.

The preparation is commonly used across conditions presenting with acute episodes that affect stability. It is relevant in clinical settings for the management of symptoms tied to conditions where functional stability becomes affected, or conditions presenting with systemic or localized discomfort.

This assistance helps maintain a sense of stability when symptoms are more noticeable. This supportive function supports the patient during difficult episodes by easing distress. The use contributes to improved day-to-day comfort during phases of increased physiological stress.

---

Quick Fact: Relevant for Symptoms that Create Noticeable Physiological Strain

The medicine is relevant in contexts marked by increased discomfort or tension, helping to ease the overall symptom burden when short-term symptomatic assistance is appropriate.

Regulatory References

1. European Medicines Agency Clinical Trials Register

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Pediatric population (infants and children) for the synchronous prophylaxis of rickets and dental caries.

Populations for whom use is contraindicated:

• Use is prohibited for patients with pre-existing metabolic conditions such as Hypercalcemia or Hypervitaminosis D, due to the Vitamin D analogue component. Use is also contraindicated in case of hypersensitivity to the active substances or excipients.
• Breastfeeding Mothers must not use the medicine, as the Dihydrotachysterol component is known to be excreted in breast milk.

Condition-specific and Environmental Eligibility Rules:

• The medicine is contraindicated if the fluoride concentration in the drinking water exceeds 0.6 ppm; total systemic fluoride intake must be precisely assessed.
• Use requires caution and close monitoring in patients with conditions affecting mineral balance, including renal impairment, a history of renal stones, or uncontrolled hyperphosphatemia.
• Use during Pregnancy is restricted and allowed only if potential regulatory benefits justify the potential risk to the fetus.

Eligibility Classifications

Regulatory documents classify use based on metabolic and environmental constraints. The profile is highly restricted, demanding mandatory exclusion for absolute contraindications and strict caution for populations with compromised renal or cardiovascular status.

The official interaction profile for this medicine is defined by two primary domains: prohibitions related to additive mineral effects and strict rules to manage component absorption.

Co-administration with other Vitamin D analogues or pharmacologic doses of Vitamin D is officially a contraindicated combination due to the high risk of severe, additive effects that can lead to hypercalcemia. The Dihydrotachysterol component's serum exposure may be decreased by Glucocorticoids/Corticosteroids, which reduce its therapeutic efficacy, and by Bile Acid Sequestrants (like Cholestyramine) and Mineral Oil, which interfere with intestinal absorption.

Specific pharmacodynamic risks are documented, including an officially increased risk of hypercalcemia when combined with Thiazide Diuretics and a heightened risk of ventricular arrhythmias with Cardiac Glycosides (e.g., Digoxin).

To ensure adequate Fluoride bioavailability, its absorption is officially classified as reduced by calcium and aluminum. A mandatory time separation of at least one hour is required between this product and the consumption of dairy products or aluminum-containing antacids. The overall interaction profile may be complicated by conditions like Hepatic Impairment, which can alter the metabolic and absorption activity of Dihydrotachysterol.

The regulatory documents define this product's interaction structure around these required constraints and classifications of risk.

How Fluor-Vigantoletten Works

The action relies on a dual mechanism influencing both mineral availability and tissue structure. The active components target distinct but complementary biological domains.

---

Hormonal Regulation of Mineral Homeostasis

The Vitamin D3 component is metabolized into its hormonal form, which acts as an agonist for the Vitamin D Receptor (VDR) primarily within the gut and kidneys. This VDR-mediated signaling enhances the absorption of dietary calcium and phosphate and regulates their systemic concentration. This physiological effect provides the fundamental mineral supply required for hard tissue mineralization and matrix formation.

---

Structural Reinforcement of Hard Tissues

The fluoride component is systemically incorporated into the crystalline lattice of developing and existing enamel and bone. It achieves this by substituting hydroxyl ions in the native mineral, hydroxyapatite, to form fluoroapatite. This substitution is a structural modification that results in a hard tissue matrix with high density and low acid solubility. The combined activity of both ingredients contributes to the formation of a highly-mineralized matrix.

Administration Route and Frequency

The approved method for administering Fluor-Vigantoletten is via the oral route, consistent with its presentation as an Oral Tablet or an Oral Solution (drops). This medication is intended for once-daily administration, a frequency pattern necessary for maintaining the continuous systemic support required for long-term prophylaxis against skeletal and dental issues.

For infants, the oral solution may be mixed with a small volume of liquid or food to facilitate consumption. Tablets for older children are generally designed to be sucked or chewed for a period before swallowing, a method intended to maximize the local, topical effect of the fluoride component on erupted teeth.

---

Dosing Principle: Age and Environmental Fluoride

Official instructions mandate that the selection of the correct Fluor-Vigantoletten strength must be based on the patient's age tier and the fluoride ion concentration in the local drinking water, measured in parts per million (ppm). This procedural requirement ensures the total systemic fluoride exposure remains within the prophylactic range, particularly during the years of tooth development. The dose of the Vitamin D component is typically set at a fixed prophylactic amount for the pediatric population.

Administration is generally initiated around 6 months of age and is intended for long-term, continuous daily use throughout childhood and adolescence, often continuing up to 16 years. A key procedural condition is the mandatory cessation of administration if the primary drinking water source contains a fluoride concentration of greater than 0.6 ppm, irrespective of the child's age.

Age Range	Water F^- Concentration <0.3 ppm	Water F^- Concentration 0.3 to 0.6 ppm
6 months to 3 years	0.25 mg F^- daily	Supplementation is not indicated
3 to 6 years	0.50 mg F^- daily	0.25 mg F^- daily

Fluor-Vigantoletten: Recent Clinical Evidence

Clinical evidence regarding the combination of Colecalciferol (Vitamin D3) and Sodium Fluoride primarily focuses on prophylaxis in infants and young children. The research explores the utility of simultaneous supplementation for two distinct, yet crucial, preventative health goals: rickets prevention (Vitamin D) and dental caries prophylaxis (Fluoride).

---

Research Findings on Combination Use

Studies in newborns and infants have investigated the availability and systemic exposure of fluoride when administered in combination with Vitamin D3. Specifically, research has shown that fluoride is absorbed and detectable in the plasma of infants receiving the combination preparation.

Key areas of investigation include:

• Plasma Fluoride Levels: Clinical studies compared plasma fluoride concentrations in infants receiving Vitamin D3 alone versus those receiving the Vitamin D3/fluoride combination. Findings indicate a measurable difference, suggesting the fluoride component is systemically available.
• Dental Caries Prevention: A long-term study examined the effect of fluoride/Vitamin D supplementation during the first year of life. Observations suggested a significant caries-preventive effect in the primary dentition of children who received the combination consistently over the first 12 months, although effects on permanent dentition were less clear.

---

Tolerability and Safety Profile in Studies

Research has explored the general safety and tolerability of this combination regimen in the target population. For example, some studies assessed safety markers, such as the TNF-alpha factor, to evaluate the cytotoxic potential of the administered fluoride dosage. Reported results indicated no signs of cytotoxicity or issues related to accumulation or overdosage within the observed treatment period.

Note: The effectiveness of fluoride supplementation is influenced by the fluoride concentration in the local drinking water, a factor that is generally considered when initiating a prophylactic regimen.

Key Studies & References

1. Prevention of dental caries with fluoride: evidence and recommendations. S3-guideline of the German Society of Dental, Oral and Craniomandibular Sciences (DGZMK)
2. Systemic and local fluoride administration: serum fluoride concentrations after intake of fluoride/vitamin D tablets in infants and young children
3. The role of vitamin D in the prevention of rickets in children - A German Consensus Statement (D-A-CH)

Common questions about Fluor-Vigantoletten (FAQ)

Q: What is Fluor-Vigantoletten and what is it used for?

Fluor-Vigantoletten is a combination medicinal product containing sodium fluoride and colecalciferol (Vitamin D3). It is used for the simultaneous prevention of rickets (a disorder causing soft and weak bones, primarily in children) and dental caries (tooth decay) in infants and young children, typically starting from the second week of life up to the end of the second year of life.

Q: How does Fluor-Vigantoletten work?

Fluor-Vigantoletten works by supplying two essential substances. Colecalciferol (Vitamin D3) helps the body absorb calcium and phosphate, which are necessary for the formation of strong, healthy bones and teeth, thereby preventing rickets. Sodium fluoride is incorporated into the developing tooth enamel, making the teeth more resistant to acids produced by bacteria, thus helping to prevent dental caries.

Q: What is the recommended dosage for Fluor-Vigantoletten?

The dosage is typically one tablet once daily. However, the exact dosage depends on the level of fluoride already available to the child (e.g., in drinking water, food, or from other sources). A pediatrician should determine the appropriate dose for an individual child to ensure the correct balance of Vitamin D and fluoride and to prevent excessive fluoride intake.

Q: Can Fluor-Vigantoletten be given with other medications or supplements?

Fluor-Vigantoletten may interact with certain other substances. It should generally not be given with other Vitamin D preparations, fluoride-containing preparations, or certain medications like phenytoin or barbiturates, as these can affect Vitamin D metabolism. Always inform your pediatrician about all medications, supplements, and vitamins your child is currently taking to check for potential interactions.

Q: What should I do if my child misses a dose?

If you forget to give your child a dose of Fluor-Vigantoletten, you should not administer a double dose to make up for the missed tablet. Simply continue with the regular daily dosage at the next scheduled time. Consistency is important for the protective effects of the treatment.

Q: What are the potential side effects of Fluor-Vigantoletten?

Side effects are generally rare when the medication is used correctly. Possible side effects could include:

• Hypersensitivity reactions (e.g., rash, itching) due to Vitamin D or fluoride.
• Hypercalcemia (too much calcium in the blood), typically only with excessive or prolonged high doses of Vitamin D.
• Dental fluorosis (mottling of tooth enamel), which can occur if the total fluoride intake (from all sources, including this medication) is too high over a prolonged period during tooth development. This is why precise dosing is crucial.

If you notice any unusual or severe symptoms, consult a doctor immediately.

Q: How long should my child take Fluor-Vigantoletten?

The duration of treatment is typically determined by the pediatrician. The recommendation is usually to administer the tablets from the second week of life until the end of the second year. However, treatment may be stopped earlier if the child is receiving sufficient fluoride through other means, such as fluoride-enriched table salt or toothpaste, or if the child is exclusively formula-fed with a highly fluoridated formula. Follow the specific advice of your child's doctor.

Storage and Disposal Requirements

The storage and disposal of Fluor-Vigantoletten must strictly follow the conditions specified on the official regulatory label.

Mandatory Storage Conditions

The product must be protected from light and stored at a temperature not exceeding 25 °C. The tablets must be kept in the original container (blister within the outer carton) to maintain protection. For safety, the medicine must always be kept out of the reach of children.

Stability and Expiration

The medicine must not be used after the expiration date (Verfalldatum) printed on the packaging.

Official Disposal Protocol

To protect the environment, unused or expired Fluor-Vigantoletten must not be discarded via wastewater or general household waste. The user is required to consult a pharmacist regarding the proper procedure for disposal of pharmaceutical waste.